Flow cytometric immunofluorescence assay for detection of antibodies to human immunodeficiency virus type 1 using insoluble precursor forms of recombinant polyproteins as carriers and antigens

被引:2
|
作者
Hu, YW
Birch, P
Balaskas, E
Zeibdawi, A
Scalia, V
TheriaultValin, SA
Gill, P
Aye, MT
机构
关键词
D O I
10.1128/JCM.34.6.1412-1419.1996
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
A new serological assay, the recombinant flow cytometric immunofluorescence assay (r-FIFA), was developed for the early detection of human immunodeficiency virus type 1 (HIV-1) antibodies by using recombinant insoluble forms of HIV-1 Gag-p45, Gag-gp41 chimeric protein, gp160, and Pol97 polyprotein as antigens and autologous carriers through flow cytometry. These recombinant proteins were expressed in insect cells by a baculovirus expression system. Eight anti-HIV-1 seroconversion panels, a low-titer anti-HIV-1 panel from Boston Biomedica Inc, (BBI), and three HIV-1 seroconversion specimens from the Provincial Health Laboratory of Ontario, Toronto, Ontario, Canada (PHL), were tested and analyzed by r-FIFA. In sensitivity comparisons between r-FIFA and tests licensed by the U.S. Food and Drug Administration, which were used to test all of the HIV-1 panels from BBI, detection of HIV-1 antibody by r-FIFA was on average greater than 20 days earlier than that by enzyme immunoassay. The sensitivity of r-FIFA has permitted the detection of HIV-1-specific immunoglobulin G (IgG), IgM, and IgA antibodies during seroconversion. A kinetic analysis of HIV-1 antibody production by r-FIFA has shown that either IgG or IgM, or both, can be detected, depending on the phase and type of the immune response in the HIV-1-infected individual. Both primary and secondary immune responses were observed during this period. The r-FIFA results suggest that implementation of r-FIFA may significantly reduce the ''window'' period from the time of infection to the time of seroconversion, with earlier detection of antibodies after initial infection. This would also make it possible for us to understand the immune response and the precise mechanisms of immunopathogenesis in the early period of HIV-1 infection.
引用
收藏
页码:1412 / 1419
页数:8
相关论文
共 50 条
  • [41] Detection of vertical transmission of human immunodeficiency virus type 1 by a commercial polymerase chain reaction assay
    Bermudez, P
    Moreno, P
    Delgado, R
    Ramos, JT
    Contreras, JR
    Noriega, AR
    EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 1996, 15 (04) : 327 - 330
  • [42] ORAL FLUID AS A SPECIMEN FOR DETECTION AND CONFIRMATION OF ANTIBODIES TO HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1
    GRANADE, TC
    PHILLIPS, SK
    PAREKH, B
    PAU, CP
    GEORGE, JR
    CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY, 1995, 2 (04) : 395 - 399
  • [43] Defining the human immunodeficiency virus type 1 transmission genetic bottleneck in a region with multiple circulating subtypes and recombinant forms
    Nofemela, Andile
    Bandawe, Gama
    Thebus, Ruwayhida
    Marais, Jinny
    Wood, Natasha
    Hoffmann, Oliver
    Maboko, Leonard
    Hoelscher, Michael
    Woodman, Zenda
    Williamson, Carolyn
    VIROLOGY, 2011, 415 (02) : 107 - 113
  • [44] DETECTION OF ANTIBODIES TO HUMAN IMMUNODEFICIENCY VIRUS TYPE-1 IN WHOLE-BLOOD AND SALIVA BY USING A PASSIVE HEMAGGLUTINATION TEST
    VASUDEVACHARI, MB
    UFFELMAN, K
    PIERCE, PF
    LANE, HC
    SALZMAN, NP
    JOURNAL OF CLINICAL MICROBIOLOGY, 1989, 27 (10) : 2384 - 2385
  • [45] Detection of human immunodeficiency virus type 1 DNA sequence using plasmonics nanoprobes
    Wabuyele, MB
    Vo-Dinh, T
    ANALYTICAL CHEMISTRY, 2005, 77 (23) : 7810 - 7815
  • [46] Novel Recombinant Virus Assay for Measuring Susceptibility of Human Immunodeficiency Virus Type 1 Group M Subtypes To Clinically Approved Drugs
    Covens, Kris
    Dekeersmaeker, Nathalie
    Schrooten, Yoeri
    Weber, Jan
    Schols, Dominique
    Quinones-Mateu, Miguel E.
    Vandamme, Anne-Mieke
    Van Laethem, Kristel
    JOURNAL OF CLINICAL MICROBIOLOGY, 2009, 47 (07) : 2232 - 2242
  • [47] VACCINE-INDUCED ANTIBODIES TO NATIVE AND RECOMBINANT HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 ENVELOPE GLYCOPROTEINS
    GORSE, GJ
    FREY, SE
    PATEL, G
    NEWMAN, FK
    BELSHE, RB
    SCHWARTZ, D
    CLEMENTS, ML
    KEEFER, M
    ROBERTS, N
    DOLIN, R
    MCELRATH, J
    COREY, L
    GRAHAM, BS
    WRIGHT, P
    MATTHEWS, T
    BOLOGNESI, D
    WALKER, MC
    FAST, P
    FERNIE, BF
    VACCINE, 1994, 12 (10) : 912 - 918
  • [48] A cluster of human immunodeficiency virus Type 1 recombinant form escaping detection by commercial genomic amplification assays
    Foglieni, Barbara
    Candotti, Daniel
    Guarnori, Irene
    Raffaele, Livia
    Berzuini, Alessandra
    Spreafico, Marta
    Orani, Anna
    Rossotti, Roberto
    Rossi, Davide
    Allain, Jean-Pierre
    Prati, Daniele
    TRANSFUSION, 2011, 51 (04) : 719 - 730
  • [49] Evaluation of a multiple-cycle, recombinant virus, growth competition assay that uses flow cytometry to measure replication efficiency of human immunodeficiency virus type 1 in cell culture
    Dykes, Carrie
    Wang, Jiong
    Jin, Xia
    Planelles, Vicente
    An, Dong Sung
    Tallo, Amanda
    Huang, Yangxin
    Wu, Hulin
    Demeter, Lisa M.
    JOURNAL OF CLINICAL MICROBIOLOGY, 2006, 44 (06) : 1930 - 1943
  • [50] A human immunodeficiency virus type 1 protease biosensor assay using bioluminescence resonance energy transfer
    Hu, K
    Clément, JF
    Abrahamyan, L
    Strebel, K
    Bouvier, M
    Kleiman, L
    Mouland, AJ
    JOURNAL OF VIROLOGICAL METHODS, 2005, 128 (1-2) : 93 - 103